



Pharmacy & Therapeutics Committee

Meeting Minutes

Thursday, May 18, 2023

7:00 a.m. to 8:45 a.m.

Video Call: <https://meet.google.com/hej-yhvk-ues>

Committee Members Present:

Cole Sloan, PharmD

Bryan Larson, PharmD

Clayton Grace, RPh

McKay Robinson, PharmD

Michelle Hofmann, MD

Susan Siegfried, MD

Committee Members Excused:

Christopher Valentine, MD

Dept. of Health/Div. of Health Care Financing Staff Present:

Jim Stamos, OHPA Director

Lisa Angelos, Pharmacy Director

Joe Busby, RPh, MBA

Ngan Huynh, PharmD

Stephanie Byrne, PharmD

Andrea Rico, CPhT

Spencer Miller, CPhT

Trevor Smith

University of Utah Drug Regimen Review Center Staff Presenter:

Lauren Heath, PharmD, MS, BCACP

Other Individuals Present:

Adam Ware, UofU Cardiology

Aimee Redhair, Biogen

Amy Hale, J&J

Brian Mooers, Bariatric Medicine
Institute

Chris Heath, Medtronic

David Moody

Derrick Grass, Novo Nordisk

Erin Nowak, AbbVie

Heidi Goodrich, Molina

Jane Stephen, Amgen

Laura Britton, HealthyU

Lauren Heath, UofU DRRC

Jason Bott, Lilly

Jean Harris, Novo Nordisk

Juliana Simonetti, UofU Weight
Management

Lillian Khor, UofU Cardiology

Melissa Abbott

Michele Puyear, Genentech

Monet Luloh, UofU DRRC

Rob Booth, AbbVie

Samantha Eshelman, SelectHealth

San Tran, Health Choice

Shannon Sturtevant, Novo Nordisk

Tina Shriner, AbbVie

Todd Dickerson, Jazz

Valerie Gonzales, UofU DRRC

Will Hancock, Novo Nordisk

Pharmacy & Therapeutics Committee

Meeting Minutes

Meeting conducted by: **Cole Sloan**

1. **Welcome & Housekeeping:** Cole Sloan opened the meeting and announced a quorum.
2. **Review and Approval of February Minutes:** Cole Sloan made a motion to approve the minutes from February. Susan Siegfried seconded the motion. All in favor, motion passed.
3. **Drug Utilization Review (DUR) Board update:** The DUR Board met in March and April the DUR board met to review Pulmonary Arterial Hypertension in Adult and Children treatments. The DUR board met last week to review the anti-obesity in overweight and obese patients.
4. **Accountable Care Organization (ACO) Update:** Report on Methodologies for Preferred Drug List Development
 - a. Health Choice..... San Tran, PharmD
 - b. HealthyU Laura Britton, PharmD
 - c. Molina Heidi Goodrich, PharmD
 - d. Select Health Samantha Eshelman, PharmD
5. **Anti-obesity Treatments Review**
 - a. Lauren Heath, PharmD from the University of Utah presented the Prescription Medications for Weight Management Utah Medicaid P&T Report.

Defined as a chronic health condition of excess adiposity which develops from many factors beyond personal choice, including environmental, socioeconomic, genetic, and psychologic contributors. In the United States, obesity is a common condition that is estimated to affect 42% of adults and 20% of children. Body mass index (BMI) Is a common population level tool to screen for excess body fat, and to identify people at risk for weight related adverse health complications.

Pharmacy & Therapeutics Committee

Meeting Minutes

Excess body fat increases the risk for developing weight-related complications. Lifestyle therapy is a cornerstone of treatment for all patients, but medications have a place in therapy for some patients since they produce greater and more sustained weight loss, compared to lifestyle changes alone.

Benefits of weight reduction among people with obesity can include prevention or improvement of Weight-Related Complications, reduced risk for premature death, and improvement in quality-of-life.

Nine medications for weight management were reviewed. Categorized into two groups: short term and long term.

Dosing frequency varies between daily to three times daily, depending on active ingredient and unique formulation. All short-term agents are approved for people 17 years of age or older.

Long-term agents are indicated for treatment of obesity or overweight with a BMI of 27 or greater, and with at least one weight related complication. Only phentermine/topiramate is a controlled substance.

All three U.S. guidelines support the option of adding weight management therapies to lifestyle interventions for adults with obesity or overweight with a BMI greater than or equal to 27 and a weight related complication. Generally, guidelines recognize obesity as a chronic condition and support using long-term adjunctive pharmacotherapy.

None of the weight management products are currently on the Utah Preferred Drug List since historically, Utah state rules have not permitted Medicaid coverage of drugs for weight loss. The PDL does include liraglutide and semaglutide formulations approved for the treatment of type 2 diabetes.

Pharmacy & Therapeutics Committee

Meeting Minutes

If it is desired to add weight management products to the PDL, the board may consider recommending that at least one weight management product, FDA approved for long-term use in adults and children, 12 years old or older, be preferred.

b. Public Comment

1. Juliana Simonetti presented for the University of Utah.
2. Brian Mooers presented for the Bariatric Medicine Institute.
3. Derrick Grass presented for Novo Nordisk.
4. Lillian Khor presented for the University of Utah

6. **Committee Discussion:**

a. The committee discussed options for anti-obesity medications.

b. Cole Sloan motioned:

“In light of coverage restrictions, recommend including at least one weight management product, FDA approved for long-term use as preferred on the PDL.”

Bryan Larson seconded. All in favor, motion passed.

Public Meeting Adjourned: Cole Sloan motioned to close the meeting. McKay Robinson seconded the motion. All in favor, motion passed.

7. **Next meeting is scheduled for** September 21, 2023 to discuss Insulin Pumps.

8. **In-Call Message Log:**

00:26:52.467,00:26:55.467

Lisa Angelos (DHHS): Please send all correspondence to our team email at medicaidpharmacy@utah.gov

00:27:15.935,00:27:18.935

Lisa Angelos (DHHS): Thank you to our ACO partners for their thoughtful presentations.

Pharmacy & Therapeutics Committee

Meeting Minutes

01:12:13.395,01:12:16.395

Bryan Larson (DHHS): Correction: Victoza is preferred on the PDL; not non-preferred as I previously mentioned.

01:18:36.653,01:18:39.653

Lillian Khor: In terms of serving both the pediatric and adult population, semaglutide is FDA approved for both.

Audio recording of all P&T meetings are available online at:

<https://medicaid.utah.gov/pharmacy/pt-committee?p=Committee%20Meeting%20Audio%20Recordings>